Speaker Profile
M.D., M.Sc., Associate Professor of Medicine and Health Research and Policy, Stanford University School of Medicine
Biography
Dr. Kurian’s research focuses on the identification of women with elevated breast and gynecologic cancer risk, and on the development and evaluation of novel techniques for early cancer detection and risk reduction. Dr. Kurian has published more than 100 peer-reviewed articles, including several in high-impact journals such as JAMA, Journal of Clinical Oncology, and Journal of the National Cancer Institute. As Director of the Stanford Women’s Clinical Cancer Genetics Program, her practice centers on women at high risk of breast and gynecologic cancers. Dr. Kurian serves on several national committees that advance the clinical and research mission of women’s cancer genetics: she develops evidence-based practice guidelines as a member of the National Comprehensive Cancer Network, and she recently led the American Society of Clinical Oncology’s Scientific Program Committee for Cancer Epidemiology and Prevention.
Talk
Genetically-targeted Prevention and Treatment of Women’s Cancers
This talk will discuss recent advances in genetic risk assessment for developing breast and gynecologic cancers, particularly the growing use of clinical next-generation sequencing. The talk will also discuss emerging approaches to genetically targeted cancer risk reduction, prevention and treatment, including the use of poly (ADP-ribose) polymerase inhibitors.
Session Abstract – PMWC 2018 Silicon Valley
Session Synopsis: New evidence-based strategists are helping cancer patients live longer and improve their quality of life. This session will review recent results from clinical trials with patients with advanced cancer show that a simple web-based system can provide major benefits to patients, including living longer, a mobile app for patients that improves quality of life, and a new class of medications that is effective at slowing the growth of metastatic breast cancer for patients with a BRCA-related genetic mutation that currently have no effective treatment options.
